Neuromyelitis Optica (Devics Syndrome) - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 70 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2014', provides an overview of the Neuromyelitis Optica (Devic's Syndrome)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuromyelitis Optica (Devic's Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Neuromyelitis Optica (Devic's Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Neuromyelitis Optica (Devic's Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neuromyelitis Optica (Devic's Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic's Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Neuromyelitis Optica (Devic's Syndrome) Overview 7
Therapeutics Development 8
Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Overview 8
Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis 9
Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Development by Companies 10
Neuromyelitis Optica (Devic's Syndrome) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Neuromyelitis Optica (Devic's Syndrome) - Products under Development by Companies 15
Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics Development 16
Alexion Pharmaceuticals, Inc. 16
Alnylam Pharmaceuticals, Inc. 17
Bionure Farma, S.L. 18
Chugai Pharmaceutical Co., Ltd. 19
HanAll Biopharma Co., Ltd. 20
MedImmune, LLC 21
Opexa Therapeutics, Inc. 22
Shenzhen Beike Biotechnology Co., Ltd. 23
Shire Plc 24
Takeda Pharmaceutical Company Limited 25
Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
ALN-CC5 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BN-201 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
C1 esterase inhibitor (human) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
eculizumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
HL-161 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
immune globulin (human) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MEDI-551 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NU-21101 + NU-21502 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
OPX-212 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SA-237 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Neuromyelitis Optica (Devic's Syndrome) - Recent Pipeline Updates 51
Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones 61
Featured News & Press Releases 61
Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program 61
Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 61
Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles 63
Dec 13, 2013: Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris Concentrated Solution for Intravenous Infusion 63
Dec 08, 2013: New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases, Demonstrate up to 98% Serum C5 Knockdown and up to 94% Inhibition of Hemolytic Activity in Non-Human Primates 64
Jul 16, 2013: Alexion's Soliris Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica 66
Jun 27, 2013: Alexion Pharma's Soliris Receives FDA Orphan Drug Designation For Treatment Of Neuromyelitis Optica 67
Oct 09, 2012: Alexion Pharma Announces Presentation Of Phase II Study Data Of Eculizumab In Patients With Relapsing Neuromyelitis Optica At ANA Annual Meeting 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70

List of Tables
Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2014 8
Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alexion Pharmaceuticals, Inc., H2 2014 16
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 17
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bionure Farma, S.L., H2 2014 18
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 19
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 20
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by MedImmune, LLC, H2 2014 21
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Opexa Therapeutics, Inc., H2 2014 22
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Shenzhen Beike Biotechnology Co., Ltd., H2 2014 23
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Shire Plc, H2 2014 24
Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Assessment by Combination Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Neuromyelitis Optica (Devic's Syndrome) Therapeutics - Recent Pipeline Updates, H2 2014 51